Cargando…
The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis
BACKGROUND: We conducted a meta-analysis to assess the efficacy and safety of mirabegron on overactive bladder (OAB) induced by benign prostatic hyperplasia (BPH) in men receiving tamsulosin therapy. METHODS: We performed the analysis by using the Preferred Reporting Items for Systematic Reviews and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004736/ https://www.ncbi.nlm.nih.gov/pubmed/31977871 http://dx.doi.org/10.1097/MD.0000000000018802 |
_version_ | 1783494790986334208 |
---|---|
author | Su, Shunye Lin, Jinlei Liang, Liqin Liu, Ludong Chen, Zhipeng Gao, Yuan |
author_facet | Su, Shunye Lin, Jinlei Liang, Liqin Liu, Ludong Chen, Zhipeng Gao, Yuan |
author_sort | Su, Shunye |
collection | PubMed |
description | BACKGROUND: We conducted a meta-analysis to assess the efficacy and safety of mirabegron on overactive bladder (OAB) induced by benign prostatic hyperplasia (BPH) in men receiving tamsulosin therapy. METHODS: We performed the analysis by using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The databases including MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were retrieved to get information regarding randomized controlled trials of mirabegron on OAB induced by BPH in men receiving tamsulosin therapy. We also searched the references of included literatures. RESULTS: Three randomized controlled trials containing a total of 1317 BPH patients were included in the analysis. Co-primary efficacy end points: the mean number of micturitions per day [the mean difference (MD) = –0.27, 95% confidence interval (CI): –0.46 to –0.09, P = .004], the urgency episodes per day (the MD = –0.50, 95% CI: –0.77 to –0.22, P = .0004), the total OAB symptom score (the MD = –0.69, 95% CI: –1.00 to –0.38, P < .0001), and mean volume voided (the MD = 10.76, 95% CI: 4.87–16.64, P = .0003) indicated that mirabegron was effective in treating OAB induced by BPH in men receiving tamsulosin therapy. Safety assessments that included treatment-emergent adverse events (odds ratio = 0.88, 95% CI: 0.68–1.13, P = .31) indicated that mirabegron was well tolerated with the exception of post-void residual urine volume (MD = 12.02, 95% CI: 6.01–18.04, P < .0001). CONCLUSIONS: This analysis demonstrates that mirabegron is an effective and safe treatment for OAB symptoms induced by BPH in men receiving tamsulosin therapy with a low occurrence of side effects. Besides, we should be aware that the administration of mirabegron might have the risk of increasing post-void residual urine volume. |
format | Online Article Text |
id | pubmed-7004736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-70047362020-02-18 The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis Su, Shunye Lin, Jinlei Liang, Liqin Liu, Ludong Chen, Zhipeng Gao, Yuan Medicine (Baltimore) 7300 BACKGROUND: We conducted a meta-analysis to assess the efficacy and safety of mirabegron on overactive bladder (OAB) induced by benign prostatic hyperplasia (BPH) in men receiving tamsulosin therapy. METHODS: We performed the analysis by using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The databases including MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were retrieved to get information regarding randomized controlled trials of mirabegron on OAB induced by BPH in men receiving tamsulosin therapy. We also searched the references of included literatures. RESULTS: Three randomized controlled trials containing a total of 1317 BPH patients were included in the analysis. Co-primary efficacy end points: the mean number of micturitions per day [the mean difference (MD) = –0.27, 95% confidence interval (CI): –0.46 to –0.09, P = .004], the urgency episodes per day (the MD = –0.50, 95% CI: –0.77 to –0.22, P = .0004), the total OAB symptom score (the MD = –0.69, 95% CI: –1.00 to –0.38, P < .0001), and mean volume voided (the MD = 10.76, 95% CI: 4.87–16.64, P = .0003) indicated that mirabegron was effective in treating OAB induced by BPH in men receiving tamsulosin therapy. Safety assessments that included treatment-emergent adverse events (odds ratio = 0.88, 95% CI: 0.68–1.13, P = .31) indicated that mirabegron was well tolerated with the exception of post-void residual urine volume (MD = 12.02, 95% CI: 6.01–18.04, P < .0001). CONCLUSIONS: This analysis demonstrates that mirabegron is an effective and safe treatment for OAB symptoms induced by BPH in men receiving tamsulosin therapy with a low occurrence of side effects. Besides, we should be aware that the administration of mirabegron might have the risk of increasing post-void residual urine volume. Wolters Kluwer Health 2020-01-24 /pmc/articles/PMC7004736/ /pubmed/31977871 http://dx.doi.org/10.1097/MD.0000000000018802 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 7300 Su, Shunye Lin, Jinlei Liang, Liqin Liu, Ludong Chen, Zhipeng Gao, Yuan The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis |
title | The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis |
title_full | The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis |
title_fullStr | The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis |
title_full_unstemmed | The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis |
title_short | The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis |
title_sort | efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis |
topic | 7300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004736/ https://www.ncbi.nlm.nih.gov/pubmed/31977871 http://dx.doi.org/10.1097/MD.0000000000018802 |
work_keys_str_mv | AT sushunye theefficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT linjinlei theefficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT liangliqin theefficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT liuludong theefficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT chenzhipeng theefficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT gaoyuan theefficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT sushunye efficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT linjinlei efficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT liangliqin efficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT liuludong efficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT chenzhipeng efficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis AT gaoyuan efficacyandsafetyofmirabegrononoveractivebladderinducedbybenignprostatichyperplasiainmenreceivingtamsulosintherapyasystematicreviewandmetaanalysis |